Micro-hospital Certificate of Need bill dies in committee
The original HB 3487 aimed to eliminate CON requirements for construction or acquisition of a small format or micro-hospital owned by a system with one or more existing licensed hospitals in the state. The version the committee took up and killed opened it up to anyone wishing to build a micro-hospital.
The new facility would have to be located to increase care capacity without jeopardizing any nearby critical access hospitals. It could include up to 25 inpatient beds, up to 25 emergency room beds, a CT scanner, an MRI scanner and other services. The cost could not exceed $100 million.
Committee counsel pointed out micro-hospitals are not defined in current code — the bill would set aside a new exception for small-format hospitals that are subject to CON.
Lead sponsor Wayne Clark, R-Jefferson, said again that the Eastern Panhandle lacks access to care. He added that micro-hospitals tend to be built in high-density suburban areas like the panhandle, rather than rural areas.
"We're going to give our citizens more access to healthcare, " he said.
Delegate Anitra Hamilton, D-Monongalia, opposed the bill, agreeing that all West Virginians need better access to healthcare. But Mon Health System built a small-format hospital in Marion and is breaking ground on one in Harrison, and went through CON for both.
A major problem, she said, is inability to recruit staff. But there is a process in place and noting hinders a health system from applying.
As we reported following the initial committee hearing on the bill, Mon Health System /Vandalia North and the West Virginia Hospital Association both opposed the bill.
A voice vote followed the debate, with a few votes for the bill and the louder majority against it.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
5 hours ago
- Miami Herald
Climate disasters can alter kids' brains — before they're even born
Climate disasters can alter kids' brains - before they're even born When Superstorm Sandy made a beeline for New York City in October 2012, it flooded huge swaths of downtown Manhattan, leaving 2 million people without electricity and heat and damaging tens of thousands of homes. The storm followed a sweltering summer in New York City, with a procession of heat waves nearing 100 degrees. For those who were pregnant at the time, enduring these extreme conditions wasn't just uncomfortable - it may have left a lasting imprint on their children's brains. That's according to a new study published in June in the peer-reviewed journal PLOS One. Using MRI scans, researchers at Queens College, City University of New York, found that children whose mothers lived through Superstorm Sandy had distinct brain differences that could hinder their emotional development. The effects were even more dramatic when people were exposed to extreme heat during their pregnancy, in addition to the tropical storm, the researchers found. "It's not just one climate stressor or one isolated event, but rather a combination of everything," Donato DeIngeniis, the lead author of the study and a doctoral student in neuropsychology at the CUNY Graduate Center, told Grist. DeIngeniis' study is the first of its kind to examine the joint effects of natural disasters and extreme heat - events that often coincide. A few years ago, scientists dubbed summer "danger season" since it's a time of colliding risks, including heat, hurricanes, wildfires, and toxic smoke. And summertime temperatures keep climbing to new heights. The study analyzed brain imaging data from a group of 34 children, approximately 8 years old, whose mothers were pregnant during Superstorm Sandy - some of whom were pregnant at the time that Sandy made landfall, and some of whom were exposed to heat 95 degrees F or higher during their pregnancy. While the researchers didn't find that heat alone had much of an impact, living through Superstorm Sandy led to an increase in the basal ganglia's volume, a part of the brain that deals with regulating emotions. While that larger size could be a compensation in response to stress, changes in the basal ganglia have been linked to behavioral challenges for children, such as depression and autism, DeIngeniis said. "What we are seeing is compelling evidence that the climate crisis is not just an environmental emergency, it is potentially a neurological one with consequence for future generations who will inherit our planet," said Duke Shereen, a co-author of the study and the director of the MRI facility at CUNY Graduate Center, in a press release. Global warming made Superstorm Sandy more damaging as a result of rising sea levels and higher ocean temperatures that might have amped up its rainfall. Yoko Nomura, a co-author of the study and a psychology professor at the Queens College, CUNY, said that the time before birth is "very, very sensitive" for development because the fetus' body is changing so drastically. The human brain grows the most rapidly in the womb, reaching more than a third of its full adult volume before birth, according to the study. Any added stress at that time, even if small, "can have a much bigger impact," Nomura said. But that extra-sensitive period also presents a window of opportunity. "Developmental science, including the science in this paper, is exciting because it not only tells us what we can do to protect children from the effects of climate change, but it also tells us when we can step in to protect children to make the greatest difference," Lindsey Burghardt, chief science officer at the Center on the Developing Child at Harvard University, said in an email. Although there's a lot of evidence that prenatal stress generally can affect child brain development, according to DeIngeniis, research on climate-related stress specifically is lacking. "It is still a field that has potential for explosive growth," said Jennifer Barkin, a professor at Mercer University School of Medicine in Macon, Georgia, who is studying the effects of last year's Hurricane Helene on maternal health. DeIngeniis' study offers concrete evidence of how climate-charged events can affect the brain, Barkin said. "People have a hard time sometimes with mental health, because it's not like you can take an X-ray and see a broken bone." But it's easier to understand imaging showing a difference in brain volume based on exposure to environmental stress, she said. Barkin, who developed an index for measuring maternal health after childbirth, says that people are beginning to pay more attention to mothers and their mental health - not just in terms of delivering a healthy baby, but over the long term. "We tend to focus things on the child's outcome, which is important, but to keep the child healthy, the mother has to be healthy, too," she said. "Because when mom's struggling, the family's going to struggle." This story was produced by Grist and reviewed and distributed by Stacker. © Stacker Media, LLC.
New York Times
11 hours ago
- New York Times
He Was Getting Weaker and More Confused. Could It Be His Drinking?
The woman struggled to get her 53-year-old husband out of the car and into the just-borrowed wheelchair. She rolled him through the crisp February air to the Emergency Department at Lawrence and Memorial Hospital in New London, Conn. They had driven straight from the neurosurgeon's office, where the physician assistant was shocked by how weak the man had become, how much worse he was than six weeks earlier when he last saw the patient. In the E.R., the man lay moaning quietly on the stretcher. His blood pressure was low, his heart rate was high. He could barely move his legs on his own, and when the E.R. doctor lifted each leg and let go, he couldn't hold them up. The doctors were worried something was compressing the man's spinal cord. The patient needed an M.R.I. right away. After the test, the man was given fluids. He hadn't been eating or drinking much for the past few weeks, his wife told the nurse. The M.R.I. showed wear and tear in his neck and some narrowing of the spinal column in his lower back, but it didn't seem enough to cause this profound weakness. Even so, the neurosurgeon who reviewed the results thought they should start him on intravenous steroids to bring down any swelling that might not have been seen on the M.R.I. That night, after his wife went home, the patient, tired and a little confused, could only provide the admitting doctor with a very basic story. His legs had started hurting a few months earlier. It began with a pins-and-needles feeling in his feet that over time moved upward. And he had terrible leg cramps. He couldn't sleep. He couldn't work. Then he couldn't walk. And now he was here. The doctor found the rest of the history in his chart. Back in September, his primary-care doctor sent him for an M.R.I. and tested him for B12 deficiency and, because this was Connecticut, for Lyme disease. His B12 was low, so she started him on a supplement. He didn't have Lyme disease. And that M.R.I. showed some osteoarthritis and mild compression, so she sent him to a neurosurgeon. He was given oral steroids and referred for physical therapy. Neither helped. By December, he was unable to leave the house. He fell several times. By January he was having problems with his memory. He missed appointments; didn't get ordered lab work. The patient had a long history of drinking, the doctor noted. The previous year, he was found guilty of driving under the influence and had to go to a court-ordered alcohol program. He was drinking less, he told the doctor. But still drinking. He had a drink earlier that day, he admitted. But only one. Want all of The Times? Subscribe.
Business Wire
a day ago
- Business Wire
Hyperfine Announces First Patients Enrolled in PRIME Study Aimed at Accelerating Adoption of AI-Powered Portable MRI in Emergency Departments
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance imaging (MRI) system for the brain—the Swoop® system—today announced the enrollment of the first patients in the PRIME (Portable Rapid Imaging for Medical Emergencies) study. This study aims to evaluate the potential of AI-powered portable MRI technology to transform triage in the emergency department (ED) setting. "Given many EDs don't have ready access to MRI, this study could alter paradigms of advanced imaging access and utilization in the ED." The PRIME study at Yale School of Medicine builds on the ACTION PMR study, which demonstrated the utility of AI-powered portable MRI in the diagnosis and management of stroke patients in emergency department settings. Expanding the scope of patients studied, the PRIME study will include a broad and diverse set of patients presenting in an emergency department and assess the technology's potential effectiveness and efficiency as a triage tool for a wide range of brain-related emergency medical conditions. Unlike ACTION PMR, the PRIME study is being conducted using the recently released next-generation Swoop® system powered by Optive AI™ software. PRIME will be one of the first studies using the new software's advanced image quality that provides sharper anatomical detail, thus potentially enabling greater pathology detection. Hyperfine's portable MRI technology has established its value in healthcare institutions, providing high-quality brain imaging at the bedside for critically ill adult and pediatric patients. Timely access to MRI in emergency department settings is still a challenge for many hospitals. Prolonged patient boarding in EDs has been cited as the top priority for hospital leaders, as evidenced in the December 2024 article in Becker's Hospital Review 1. By removing the traditional barriers associated with access to conventional MRI scanners—such as wait times, shortage of dedicated MRI technologists, cost, and immobility—portable MR imaging enables faster, more efficient decision-making in emergency department settings. The PRIME study will enroll patients in a Level 1 emergency department, assessing a broad spectrum of emergency medical conditions. 'By evaluating the potential of portable MRI in this real-world setting, this study aims to determine if a portable MRI system can provide diagnostic imaging capabilities that can be quickly integrated into the ED workflow to improve patient care decisions in real time,' said Dr. Kevin Sheth, Professor of Neurology and Neurosurgery at the Yale School of Medicine and principal investigator for the PRIME study, who is working in close collaboration with his co-PI Dr. Adam De Havenon. 'Given many EDs don't have ready access to MRI, this study could alter paradigms of advanced imaging access and utilization in the ED,' said Dr. Charles Wira, Associate Professor of Emergency Medicine at Yale University. 'The Hyperfine portable MRI system could immediately provide ED clinicians and consulting physicians with critical imaging data at the point of care, helping them to make more informed, faster decisions when every second counts.' 'Hyperfine is thrilled to collaborate with Yale on this transformative project. The Yale team has worked with portable brain MRI since the technology's early days,' said Maria Sainz, President and CEO of Hyperfine. 'Through the PRIME study, they demonstrate a bold vision for how portable MRI can accelerate triage in emergency care. The next-generation Swoop® system, powered by Optive AI™ software, provides more clinically valuable image quality that we expect will drive greater adoption in the emergency setting and help address the widespread clinical and economic challenges of ED boarding.' Hyperfine is committed to advancing the role of portable MRI in emergency care of the brain, one of the sites of care where access to conventional MRI is challenging. The PRIME study represents a strategic initiative within the broader Hyperfine hospital market strategy to drive commercial growth, demonstrating how the placement of portable MRI systems in emergency departments can unlock timely diagnostic access and improve clinical workflows at the point of care. For more information about the Swoop® system, please visit For more information about the PRIME study, including enrollment details and eligibility criteria, please visit 1. ED boarding: 10 things to know. Becker's Hospital Review. About the Swoop® Portable MRI Systems The Swoop® Portable MR Imaging® Systems are U.S. Food and Drug Administration (FDA) cleared for brain imaging of patients of all ages. They are portable, ultra-low-field magnetic resonance imaging devices for producing images that display the internal structure of the head where full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis. About Hyperfine, Inc. Hyperfine, Inc. (Nasdaq: HYPR) is the groundbreaking health technology company that has redefined brain imaging with the Swoop® system—the first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of professional care. The mission of Hyperfine, Inc. is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine, Inc. scientists, engineers, and physicists developed the Swoop® system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. For more information, visit The Hyperfine logo, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc. The Swoop logo, Optive AI logo, and Optive AI are trademarks of Hyperfine, Inc. Forward-Looking Statements This press release includes 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. Actual results of Hyperfine, Inc. (the 'Company') may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as 'expect,' 'estimate,' 'project,' 'budget,' 'forecast,' 'anticipate,' 'intend,' 'plan,' 'may,' 'will,' 'could,' 'should,' 'believes,' 'predicts,' 'potential,' 'continue,' and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's goals and commercial plans, the benefits of the Company's products and services, and the Company's future performance and its ability to implement its strategy. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the success, cost and timing of the Company's product development and commercialization activities, including the degree that the Swoop® system is accepted and used by healthcare professionals; the impact of COVID-19 on the Company's business; the inability to maintain the listing of the Company's Class A common stock on the Nasdaq; the Company's inability to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the inability of the Company to raise financing in the future; the inability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of the Company to maintain its existing or future license, manufacturing, supply and distribution agreements and to obtain adequate supply of its products; the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; the size and growth potential of the markets for the Company's products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company's products and services and reimbursement for medical procedures conducted using the Company's products and services; the Company's estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company's financial performance; and other risks and uncertainties indicated from time to time in Company's filings with the Securities and Exchange Commission, including those under 'Risk Factors' therein. The Company cautions readers that the foregoing list of factors is not exclusive and that readers should not place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.
